APMD
Apnimed, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
18.67
▲ 0.02 (0.11%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
18.66
Prev close
18.65
Day high
19.40
Day low
18.25
Volume
63.88K
Market cap
$777.25M
P/E (TTM)
2.59
52W range
16.12 – 35.29
Day trading desk
Gap from prior close
+0.05%
Prior close 18.65
VWAP
18.54
+0.71% from price
Relative volume
0.11×
Quiet session
Session range
6.32%
18.25 – 19.40
Position in range
36%
Mid range
ATR (14D)
2.63
14.09% of price
Prior day high
21.95
PDH
Prior day low
18.34
PDL
Bid / ask spread
—
Quote not published
Session volume
63.19K
Avg 558.59K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.79%
-16.3%
1M
-35.15%
-36.2%
3M
—
-3.0%
6M
—
-14.5%
YTD
-25.32%
-38.8%
1Y
—
-15.3%
3Y
—
-81.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on APMD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
14.82M
Total on file
Fundamentals
Market cap$777.25M
Enterprise value$929.90M
Revenue (TTM)$115.12M
Gross profit$108.10M
EBITDA$35.90M
Net income$170.74M
EPS (TTM)$7.22
Free cash flow—
Total cash$172.80M
Total debt$80.35M
Book value / share$-36.69
Shares outstanding41.63M
Float20.46M
Short % of float—
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E2.59
Forward P/E-4.70
PEG ratio—
Price / sales—
Price / book—
EV / revenue8.08
EV / EBITDA25.91
Gross margin93.90%
Operating margin-96.89%
Profit margin142.10%
Return on equity—
Return on assets—
Debt / equity115.18
Current ratio5.19
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $38.47M | $8.01M | +380.1% |
| Operating revenue | $38.47M | $8.01M | +380.1% |
| Cost of revenue | $6.69M | $3.37M | +98.7% |
| Gross profit | $31.77M | $4.64M | +584.3% |
| Research & development | $62.10M | $97.38M | -36.2% |
| Selling, general & admin | $23.49M | $21.50M | +9.2% |
| Total operating expense | $85.59M | $118.88M | -28.0% |
| Operating income | -$53.82M | -$114.23M | +52.9% |
| Net interest income | $1.41M | $5.68M | -75.2% |
| Pre-tax income | -$932.00K | -$108.55M | +99.1% |
| Tax provision | $0 | $51.00K | -100.0% |
| Net income | -$932.00K | -$111.31M | +99.2% |
| Net income to common | -$932.00K | -$111.31M | +99.2% |
| Basic EPS | -0.03 | -3.87 | +99.2% |
| Diluted EPS | -0.03 | -3.87 | +99.2% |
| EBIT | -$53.82M | -$114.23M | +52.9% |
| EBITDA | -$53.79M | -$114.21M | +52.9% |
| Basic shares | 26.63M | 28.76M | -7.4% |
| Diluted shares | 26.63M | 32.14M | -17.1% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $41.89M | $68.35M | -38.7% |
| Cash & short-term investments | $41.89M | $68.35M | -38.7% |
| Accounts receivable | $959.00K | $1.11M | -14.0% |
| Total current assets | $45.05M | $73.25M | -38.5% |
| Property, plant & equipment | $901.00K | $1.16M | -22.1% |
| Total assets | $72.87M | $109.22M | -33.3% |
| Total current liabilities | $110.88M | $42.36M | +161.8% |
| Long-term debt | $40.65M | — | — |
| Total debt | $41.52M | $1.09M | +3,691.7% |
| Total liabilities | $445.66M | $357.84M | +24.5% |
| Retained earnings | -$397.34M | -$269.15M | -47.6% |
| Shareholder equity | -$372.78M | -$248.62M | -49.9% |
| Working capital | -$65.82M | $30.89M | -313.1% |
| Net tangible assets | -$372.78M | -$248.62M | -49.9% |
| Shares issued | 39.82M | 39.82M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$58.05M | -$108.60M | +46.5% |
| Depreciation & amortisation | $27.00K | $23.00K | +17.4% |
| Stock-based compensation | $3.91M | $3.03M | +28.9% |
| Change in working capital | -$29.59M | -$238.00K | -12,333.2% |
| Operating cash flow | -$77.83M | -$110.21M | +29.4% |
| Capital expenditure | — | -$70.00K | — |
| Investing cash flow | $0 | $151.96M | -100.0% |
| Financing cash flow | $51.37M | $51.00K | +100,629.4% |
| Free cash flow | -$77.83M | -$110.28M | +29.4% |
| End cash position | $41.89M | $68.35M | -38.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $12.08M | $84.81M | $17.11M | $3.13M | -85.8% |
| Operating revenue | $12.08M | $84.81M | $17.11M | $3.13M | -85.8% |
| Cost of revenue | $1.21M | $2.16M | $1.72M | $1.32M | -44.0% |
| Gross profit | $10.87M | $82.65M | $15.39M | $1.81M | -86.8% |
| Research & development | $9.90M | $8.10M | $15.97M | $23.46M | +22.2% |
| Selling, general & admin | $12.67M | $6.51M | $5.35M | $5.47M | +94.8% |
| Total operating expense | $22.57M | $14.61M | $21.32M | $28.93M | +54.5% |
| Operating income | -$11.70M | $68.04M | -$5.94M | -$27.11M | -117.2% |
| Net interest income | $970.00K | $218.00K | $309.00K | $431.00K | +345.0% |
| Pre-tax income | $126.11M | $70.37M | -$5.63M | -$26.68M | +79.2% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | $125.94M | $70.37M | -$69.47M | -$28.65M | +79.0% |
| Net income to common | $125.94M | $70.37M | -$69.47M | -$28.65M | +79.0% |
| Basic EPS | 3.16 | 2.45 | -2.42 | -1.00 | +29.1% |
| Diluted EPS | 3.16 | 2.12 | -2.42 | -1.00 | +49.2% |
| EBIT | -$11.70M | $68.04M | -$5.94M | -$27.11M | -117.2% |
| EBITDA | -$11.70M | $68.05M | -$5.93M | -$27.11M | -117.2% |
| Basic shares | 39.82M | 28.76M | 28.76M | 28.76M | +38.5% |
| Diluted shares | 39.82M | 32.14M | 32.14M | 32.14M | +23.9% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $172.80M | $328.88M | -47.5% |
| Cash & short-term investments | $172.80M | $328.88M | -47.5% |
| Accounts receivable | $690.00K | $876.00K | -21.2% |
| Total current assets | $184.77M | $332.00M | -44.3% |
| Property, plant & equipment | $10.66M | $10.61M | +0.5% |
| Total assets | $195.46M | $342.63M | -43.0% |
| Total current liabilities | $35.58M | $38.39M | -7.3% |
| Long-term debt | $79.60M | $46.10M | +72.7% |
| Total debt | $80.35M | $46.91M | +71.3% |
| Total liabilities | $371.64M | $85.04M | +337.0% |
| Retained earnings | -$203.69M | -$186.97M | -8.9% |
| Shareholder equity | -$176.18M | $257.59M | -168.4% |
| Working capital | $149.19M | $293.61M | -49.2% |
| Net tangible assets | -$176.18M | $257.59M | -168.4% |
| Shares issued | 39.82M | 39.82M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | $126.11M | $70.37M | -$5.63M | -$26.68M | +79.2% |
| Depreciation & amortisation | $7.00K | $6.00K | $6.00K | $7.00K | +16.7% |
| Stock-based compensation | $1.19M | $929.00K | $866.00K | $802.00K | +28.2% |
| Change in working capital | -$65.75M | -$89.07M | -$12.67M | -$2.63M | +26.2% |
| Operating cash flow | -$18.11M | -$19.81M | -$17.37M | -$28.45M | +8.6% |
| Financing cash flow | $44.37M | $24.81M | $16.29M | $0 | +78.8% |
| Free cash flow | -$18.45M | -$19.81M | -$17.37M | -$28.45M | +6.9% |
| End cash position | $172.80M | $46.89M | $38.82M | $39.90M | +268.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.34 | -0.42 | -22.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.60 | 2 | $0 | — |
| Next quarter | -0.72 | 2 | $0 | — |
| Current year | -0.06 | 1 | $90.85M | — |
| Next year | -3.98 | 4 | $22.44M | -75.3% |
Analyst targets & ownership
Mean target$50.33
High target$60.00
Low target$41.00
Implied upside169.59%
Analyst count3
ConsensusNONE
Strong buy / Buy0 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders35.61%
Held by institutions23.29%
Institutions holding17
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.33
-12.48% from price
SMA 20
23.79
-21.53% from price
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
21.87
-14.62% from price
EMA 26
23.85
-21.71% from price
EMA 50
—
—
RSI (14)
34.1
Neutral
MACD (12,26,9)
-1.98
Hist -0.47
ATR (14)
2.63
14.09% of price
Realised vol 30D
94.4%
Annualised
Bollinger upper
29.66
20, 2σ
Bollinger lower
17.93
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
94.4%
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
-42.7%
Peak to trough
Max drawdown 5Y
-42.7%
Peak to trough
ATR 14
2.63
14.09% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
879.68K
Prior 407.56K
Change vs prior
+115.8%
Shorts adding
% of float
—
—
% of shares out
2.11%
Against total outstanding
Days to cover
2.7
Liquid
Float
20.46M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 26 | LifeSci Capital | INITIATED | — | Outperform |
| Aug 25, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Aug 25, 26 | Evercore ISI Group | INITIATED | — | Outperform |
| Aug 25, 26 | B of A Securities | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Headlines
Bank of America Puts These 2 Under-the-Radar IPO Stocks on Its Buy List
TipRanks · 20h ago
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Trefis · 15d ago
Apnimed Q2 Swings to Earnings, Revenue Declines
MT Newswires · 29d ago
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 29d ago
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 33d ago
BofA makes bullish call on newly public biotech stock
TheStreet · 40d ago
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Trefis · 42d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.